Canine NGAL antibody and antigen (recombinant protein)
Diagnostic anti-Canine NGAL antibodies pairs and antigen for animal health (animal Dog/Canine kidney injury) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-CAN-NGAL-Ag01 | Recombinant Canine NGAL protein | 3090 |
GMP-CAN-NGAL-Ab01 | Anti-Canine NGAL mouse monoclonal antibody (mAb) | 1953 |
GMP-CAN-NGAL-Ab02 | Anti-Canine NGAL mouse monoclonal antibody (mAb) | 1953 |
GMP-CAN-NGAL-Ab03 | Anti-Canine NGAL human monoclonal antibody (mAb) | 1953 |
GMP-CAN-NGAL-Ab04 | Anti-Canine NGAL human monoclonal antibody (mAb) | 1953 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-CAN-NGAL-Ag01 |
Product Name | Recombinant Canine NGAL protein |
Target/Biomarker | Canine Neutrophil gelatinase-associated lipocalin (NGAL) |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Canine Neutrophil gelatinase-associated lipocalin antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in NGAL level test of animal Dog/Canine with kidney injury. |
Tag | His |
Products description | Recombinant Canine NGAL protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-CAN-NGAL-Ab01, GMP-CAN-NGAL-Ab02 |
Product Name | Anti-Canine NGAL mouse monoclonal antibody (mAb) |
Target/Biomarker | Canine Neutrophil gelatinase-associated lipocalin (NGAL) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Canine Neutrophil gelatinase-associated lipocalin antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-NGAL antibodies in NGAL level test of animal Dog/Canine with kidney injury. |
Tag | mFc |
Products description | Anti-Canine NGAL mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-NGAL antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-CAN-NGAL-Ab03, GMP-CAN-NGAL-Ab04 |
Product Name | Anti-Canine NGAL human monoclonal antibody (mAb) |
Target/Biomarker | Canine Neutrophil gelatinase-associated lipocalin (NGAL) |
Expression platform | CHO |
Isotypes | Human IgG1 |
Bioactivity validation | Recombinant Canine Neutrophil gelatinase-associated lipocalin antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-NGAL antibodies in NGAL level test of animal Dog/Canine with kidney injury. |
Tag | hFc |
Products description | Anti-Canine NGAL human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-NGAL antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
Canine NGAL, or Neutrophil Gelatinase-Associated Lipocalin, is a relatively small but mighty glycoprotein with far-reaching significance in the realm of canine health. It operates as a sentinel, a vigilant guardian of the intricate renal machinery within a dog's body, specifically, the renal tubules. Synthesized and released by various cells, including neutrophils and renal tubular cells, Canine NGAL is poised to respond to renal distress with remarkable speed. When acute kidney injury (AKI) strikes, whether due to toxins, infections, or other factors, Canine NGAL swiftly enters the bloodstream. This rapid release positions NGAL as one of the earliest indicators of renal dysfunction in dogs, often preceding other traditional markers. Canine NGAL's journey through the renal tubules holds critical insights into its role as a biomarker. In healthy dogs, the majority of NGAL is reabsorbed by the renal tubules and catabolized. However, in the presence of renal injury or stress, this finely tuned process is disrupted. As a result, NGAL levels rise, serving as a beacon of distress and an early warning system for veterinarians. The true strength of Canine NGAL is its sensitivity and specificity. It detects renal injury at its inception, often before clinical symptoms manifest. This early detection is a game-changer in the management of AKI, allowing for prompt intervention and treatment. Timely action can significantly improve the prognosis for canine patients, preserving both their quality of life and longevity.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.